The reduction in price target by Stephens & Co. suggests a downward revision of future price expectations for Akoya Biosciences, which could lead to a negative short-term impact on the stock price. However, maintaining an Overweight rating indicates a continued positive outlook on the company's fundamentals, which may mitigate some negative sentiment.